Thursday, July 23

Browsing: Limited

Support

Case Study: Individualizing Frontline Therapy in an Older Patient With Comorbidities and Limited Support

By NewsCancerJuly 23, 20260

This segment presents a contrasting case: an older patient with a classic sensitizing mutation, lower disease burden, no central nervous…

Diagnosis

Third-Line Therapy Shows Limited Efficacy in Real-World aGVHD Population

By NewsCancerApril 1, 20260

Third-line interventions demonstrated limited benefits among patients with acute graft-versus-host-disease and gastrointestinal involvement (GI-aGVHD) who were refractory to ruxolitinib (Jakafi)…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

The MARIPOSA Regimen: Efficacy and Toxicity Management in Frontline EGFR-Mutant NSCLC

Case Study: Selecting Frontline Therapy in Higher-Risk EGFR-Mutant NSCLC With Brain Metastases

Case Study: Individualizing Frontline Therapy in an Older Patient With Comorbidities and Limited Support

Browsing: Limited

Case Study: Individualizing Frontline Therapy in an Older Patient With Comorbidities and Limited Support

Third-Line Therapy Shows Limited Efficacy in Real-World aGVHD Population

The MARIPOSA Regimen: Efficacy and Toxicity Management in Frontline EGFR-Mutant NSCLC

Case Study: Selecting Frontline Therapy in Higher-Risk EGFR-Mutant NSCLC With Brain Metastases

Case Study: Individualizing Frontline Therapy in an Older Patient With Comorbidities and Limited Support

A spatial view of tumor neoantigen recognition

The MARIPOSA Regimen: Efficacy and Toxicity Management in Frontline EGFR-Mutant NSCLC

Case Study: Selecting Frontline Therapy in Higher-Risk EGFR-Mutant NSCLC With Brain Metastases

Case Study: Individualizing Frontline Therapy in an Older Patient With Comorbidities and Limited Support

A spatial view of tumor neoantigen recognition

Latest Post

The MARIPOSA Regimen: Efficacy and Toxicity Management in Frontline EGFR-Mutant NSCLC

Case Study: Selecting Frontline Therapy in Higher-Risk EGFR-Mutant NSCLC With Brain Metastases

Case Study: Individualizing Frontline Therapy in an Older Patient With Comorbidities and Limited Support

Subscribe to Updates

What's Hot

Browsing: Limited